Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib

NCT07633626 is registered in ClinicalTrials.gov with Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo as lead sponsor.

NCT NCT07633626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07633626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib
Lead sponsor
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Phase
Observational
Overall status
Recruiting
Start date
March 10, 2026
Completion date
November 10, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced alk/ros1-positive nsclc, alk-positive non-small cell lung cancer (nsclc), carcinoma, non-small-cell lung (nsclc), cognitive dysfunction, depression, lung adenocarcinoma